PsilodexMedication × psilocybin
Your list , 0 items
General prescriptions
Brand names
Tryvio
Reviewed 2026-10-04

Aprocitentan

An endothelin receptor blocker, FDA-approved as add-on treatment for high blood pressure not controlled by other medicines.

psilodex.org/m/aprocitentan · data v2026.10.05

Clinical contraindication
None listed
No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence
No psilocybin data
Half-life
~41 h
Approximate, in adults. Source under Interaction below.
Named in state rules?
Not namedColorado Condition rules (3)
Not namedOregon
PendingNew Mexico
Cite asPsilodex, “Aprocitentan”, v2026.10.05. psilodex.org/m/aprocitentan

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

FDA-approved for
  • High blood pressure not adequately controlled on other drugs (add-on)
Sources [1]
Other safety

Boxed warning: contraindicated in pregnancy because it may cause fetal harm.

About the medication itself, separate from any interaction with psilocybin.

Sources [1]

01 Interaction with psilocybin

ND

It lowers blood pressure and may lessen psilocybin's blood pressure rise. Lab findings suggest a theoretical effect on how the body clears psilocybin.

Detail Aprocitentan lowers blood pressure and may lessen psilocybin's brief blood pressure rise; this has not been studied with psilocybin. In lab studies, it inhibited the enzymes UGT1A1 and UGT2B7. The body removes psilocin mainly by glucuronidation (a UGT-driven process) and conversion to 4-HIAA. In lab studies, MAO-A, CYP2D6 and CYP3A4 also metabolized psilocin (Thomann 2024). So an effect on psilocin levels is possible only in theory. Separately, its half-life is long (about 41 hours). Sources [1][2]

Human data with psilocybin
No psilocybin data; based on how it works
Half-life
~41 h (effective) (FDA label, checked 2026-10-04)
Evidence types on this record
No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

3 listed (1 possible) · counted on reports
Liver injury
The label or source warns of liver injury, from raised liver enzymes to liver failure. Liver disease also affects how the body clears psilocin. Sources [1]
Lowers blood pressure or causes orthostasis
Lowers blood pressure, or causes a drop on standing (orthostasis) that can bring dizziness or fainting. Sources [1]
UGT inhibition (theoretical effect on psilocin levels)Possible
Inhibits UGT enzymes (glucuronidation), the main route by which the body clears psilocin. In theory this could raise psilocin levels or lengthen the effect.Possible: The source describes the effect as small, seen only in laboratory or animal studies, or theoretical. Sources [1]

03 State rules

Plain-language summary · official text governs
CO4 CCR 755-1
Not namedCondition rules (3)

No provision names this medication or its class.

Colorado · checked 2026-10-04
OROAR 333-333
Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04
NM7.35.3 NMAC (proposed)
Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

Screening items in state rules

This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.

  • Hypertension (provision applies if uncontrolled)
    • CO 2.5(A)(2) · Clinical Facilitator licensees
    • CO 6.16(F)(2)(a) · Facilitators without a clinical facilitator license
    • CO 6.16(F)(1) · All licensees

05 Sources

2
  1. TRYVIO (aprocitentan) tablets · FDA label (DailyMed) — Liver injury: 5.2 Hepatotoxicity "Elevations of aminotransferases and hepatotoxicity are known effects of ERAs, including TRYVIO." | Lowers blood pressure or causes orthostasis: 1 Indications and Usage "TRYVIO, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs." | UGT inhibition (theoretical effect on psilocin levels): 12.3 Pharmacokinetics (In Vitro Studies) "UGT enzymes: Aprocitentan is a substrate and inhibitor of UGT1A1 and UGT2B7." | 12.3 Pharmacokinetics "The aprocitentan effective half-life is approximately 41 hours" | Boxed Warning "TRYVIO is contraindicated for use during pregnancy because it may cause fetal harm if used by pregnant patients." | revised 2026-08
  2. Thomann J, Kolaczynska KE, Stoeckmann OV, et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Front Pharmacol 2024;15:1391689. — Psilocin metabolism: glucuronidation and 4-HIAA; MAO-A, CYP2D6 and CYP3A4 metabolized psilocin in vitro.

Record history

  • v2026.10.02First published.
  • 2026-10-04Last reviewed against its sources.

Report an error in this record →

Before you startTerms 2026-10-01

What Psilodex is, and isn't.

  1. 01Psilodex summarizes published evidence and public state rules. It does not decide whether you can safely use psilocybin or take part in services, and it is not medical advice.
  2. 02Psilodex presents information only. Do not stop or change a medication without talking with the prescriber. Bring the report to them.
  3. 03Your searches and list stay in this browser and are not sent to us. Opening a medication's page is an ordinary web request, so our hosting providers see which page was opened. What we can and can't see.

In an emergency, call 911. For a mental health crisis, call or text 988. Full terms and privacy.